[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bridget A. Ross, a director of LeMaitre Vascular (LMAT), reported exercising 2,500 vested stock options on 08/08/2025 with an exercise price of $37.29, and concurrently selling 2,500 common shares at $94.00 per share. The option exercised was fully vested and had an expiration date of 12/02/2025. The sequence increased her direct holdings to 5,416 shares then, after the sale, left her with 2,916 shares of common stock beneficially owned.

Insights

Securities Analyst

TL;DR: Director exercised vested options and sold the same number of shares; net direct ownership is 2,916 shares.

The filing documents a routine option exercise (2,500 shares at a $37.29 strike) followed immediately by a sale of those 2,500 shares at $94.00. This left the reporting director with 2,916 directly owned shares. The option was fully vested with a 12/02/2025 expiration, so there is no remaining derivative position from that grant. From a market-impact perspective this is a single-person insider liquidity event and does not, by itself, indicate a change in company fundamentals.

Corporate Governance Expert

TL;DR: Disclosure shows a vested-option exercise and disposition by a director; the report is complete and notes vesting and expiration.

The Form 4 discloses both the acquisition from option exercise and the contemporaneous disposition of the same 2,500 shares, with clear reporting of prices and post-transaction share counts. The explanatory footnotes explicitly state the shares were acquired upon exercise and that the option was fully vested and exercisable. This meets standard Section 16 transparency expectations; the filing contains no additional governance actions or changes in role.

Insider Trade Summary

Net Seller: 2,500 shares ($235,000)

Net Sell 3 txns

Insider Ross Bridget A

Role Director

Sold 2,500 shs ($235K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$37.29	$93K
Sale	Common Stock	2,500	$94.00	$235K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 5,416 shares (Direct)

Footnotes (1)

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. This option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Bridget A

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		M		2,500(1)	A	$37.29	5,416	D
Common Stock	08/08/2025		S		2,500	D	$94	2,916	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.29	08/08/2025		M			2,500	12/02/2020(2)	12/02/2025	Common Stock	2,500	$0	0	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

	/s/ Nathan Ulrich	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.